Health disparities in tuberculosis incidence, prevalence, and mortality in China (1990 to 2016) using data from the Global Burden of Disease Study 2016: a longitudinal analysis

Abstract Visceral leishmaniasis (VL) is a neglected tropical disease which contributes to the mortality and morbidity significantly in India and Brazil. This study was planned to compare the trends of incidence, prevalence, death and disability-adjusted life years (DALY) of VL burden in India and Brazil from 1990 to 2019 using Global burden of disease study (GBD) data. The metrics are presented as age-standardized rates per 100,000 inhabitants with their respective uncertainty intervals (95%UI) and relative percentages of change. The decline in the Incidence rate is more in case of India (16.82 cases per 100,000 in 1990 to 0.60cases in 2019) as compared to Brazil (3.12 cases per 100,000 in 1990 to 2.65 cases in 2019). The annualized rate of change in number of prevalent cases for India is -0.95 (95% UI, -0.98 to -0.91) whereas for Brazil it is -0.06 (95% UI, -0.41 to 0.52). The annualized rate of change in number of DALY for India is -0.94 (95% UI, -0.96 to -0.92) whereas for Brazil it is -0.09 (95% UI, -0.25 to 0.28). The annualized rate of change in number of deaths for India is -0.93 (95% UI, -0.95 to -0.92) whereas for Brazil it is increasing i.e. 0.04 (95% UI, -0.12 to 0.51). India achieves significant reduction in the age standardized incidence, prevalence, mortality and DALY of VL as compare to Brazil during the period of 1990 to 2019. A multi-centric study is required to assess bottleneck in the existing strategies of VLSCP in Brazil.

Download Full-text

Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 global burden of disease study

BMC Public Health ◽

10.1186/s12889-020-09835-7 ◽

2020 ◽

Vol 20 (1) ◽

Author(s):

Hairong He ◽

Hongjun Xie ◽

Yule Chen ◽

Chengzhuo Li ◽

Didi Han ◽

...

Keyword(s):

Bladder Cancer ◽

Latin America ◽

Burden Of Disease ◽

Western Europe ◽

Global Burden Of Disease ◽

Global Burden ◽

Disability Adjusted Life ◽

Life Years ◽

Using Data ◽

Disease Study

Abstract Background The aim of this study is to describe the prevalence and mortality of bladder cancer (BCa) using data obtained in the Global Burden of Disease study performed in 2017 (GBD 2017). Methods Data on BCa for 2017, including prevalence, mortality, and disability-adjusted life years (DALYs), were obtained from GBD 2017 at the global, regional, and national levels. We also analyzed the association of BCa burden with the country development level. Results There were 2.63 million BCa cases estimated from the GBD 2017 data, with 200,000 persons dying of BCa, resulting in 3.60 million DALYs in 2017. The age-standardized prevalence (ASP) of BCa was 32.91/100,000 persons, and age-standardized death rate (ASDR) was 2.57/100,000 persons. The ASP and ASDR of BCa were higher in males than in females, and higher in people older than 60 years. The ASP and ASDR of BCa were higher in Western Europe and Central Europe than in South Asia, Andean Latin America, and Central Latin America, and higher in countries with a higher sociodemographic index (SDI). Correlation analysis identified that the ASP and ASDR of BCa were positively correlated with the country SDI (P < 0.0001 and ρ = 0.68 for ASP, and P = 0.0048 and ρ = 0.20 for ASDR). In addition, 33.72% deaths and 36.80% DALYs caused by BCa could be attributed to smoking globally. Conclusion The prevalence and mortality of BCa were very high in 2017, especially in high-SDI countries. Smoking-cessation strategies should be strengthened to control the burden associated with BCa.

Download Full-text

Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013

The Lancet ◽

10.1016/s0140-6736(15)60692-4 ◽

2015 ◽

Vol 386 (9995) ◽

pp. 743-800 ◽

Cited By ~ 2866

Author(s):

Theo Vos ◽

Ryan M Barber ◽

Brad Bell ◽

Amelia Bertozzi-Villa ◽

Stan Biryukov ◽

...

Keyword(s):

Chronic Diseases ◽

Burden Of Disease ◽

Global Burden Of Disease ◽

Global Burden ◽

Systematic Analysis ◽

Disease Study ◽

Years Lived With Disability ◽

Incidence Prevalence

Download Full-text

Trends in burden of multidrug-resistant tuberculosis in countries, regions, and worldwide from 1990 to 2017: results from the Global Burden of Disease Study

10.21203/rs.3.rs-63071/v1 ◽

2020 ◽

Author(s):

Zejin Ou ◽

Danfeng Yu ◽

Yuanhao Liang ◽

Wenqiao He ◽

Yongzhi Li ◽

...

Keyword(s):

Burden Of Disease ◽

Multidrug Resistant ◽

Global Burden Of Disease ◽

Global Burden ◽

Resistant Tuberculosis ◽

Multidrug Resistant Tuberculosis ◽

Mdr Tb ◽

Disease Study ◽

Increasing Trends ◽

Incidence Prevalence

Abstract Background This study aimed to estimate the trends of multidrug-resistant tuberculosis (MDR-TB), which can be used to inform health strategies.Methods Data were collected from the Global Burden of Disease Study 2017. The estimated annual percentage change (EAPCs) were calculated to assess the trends of MDR-TB burden from 1990 to 2017.Results Globally, the ASR of MDR-TB burden including incidence, prevalence, death and disability-adjusted life years (DALYs) had pronounced increasing trends from 1990 to 1999, with the EAPCs were 17.63(95% confidence interval [CI]: 10.77 to 24.92), 17.57(95%CI: 11.51 to 23.95), 21.21(95%CI:15.96 to 26.69), and 21.90(95%CI: 16.55 to 27.50), respectively. Particularly, the largest increasing trends were seen in areas and countries of low and low-middle sociodemographic index (SDI). However, the trends in incidence, prevalence, death and DALYs of MDR-TB decreased globally from 2000 to 2017, with the respective EAPCs were −1.37(95%CI: −1.62 to −1.12), −1.32(95%CI: −1.38 to −1.26), −3.30(95%CI: −3.56 to −3.04) and −3.32(95%CI: −3.59 to −3.06). Decreasing trends of MDR-TB were observed in most regions and countries, particularly that of death and DALYs in Slovenia were −18.96(95%CI: −20.82 to −17.06) and −19.35 (95%CI: −21.10 to −17.55), respectively. Whereas the pronounced increasing trends of MDR-TB occurred in Papua New Guinea, Singapore, and Australia.Conclusions the ASR of incidence, prevalence, death and DALYs of MDR-TB showed decreasing trends from 2000 to 2017. However, the MDR-TB burden remains a substantial challenge to the TB control globally, and requires effective control strategies and healthcare.

Download Full-text